Microenvironmental support of malignant cells by monocytes through release of inflammatory proteins has been reported in CLL and WM, and their inhibition by zanubrutinib and other BTK inhibitors may contribute to their mechanism of action (42, 43). Here, BTK is linked to B-cell chronic lymphocytic leukemia.